2 Surprising Bargain Stocks for Value Investors
Nu Skin and Herbalife look tempting for investors looking to get in on the cheap.
Ouch! I was prepared for some volatility when I invested in a skin-care company that relies on direct selling. But I really didn’t expect to get skinned alive so soon after I bought the stock. For those of us who consider ourselves value investors, however, suffering through what we hope are temporary setbacks is just part of the game.
Perhaps I should back up and explain. In mid July, I bought 148 shares of Nu Skin Enterprises (symbol NUS), which sells skin creams and other anti-aging products. At $67.80, the stock had already been cut in half since the start of the year and was selling at 11 times projected year-ahead earnings. The shares looked cheap. Unfortunately, they got much cheaper, falling to as low as $43.50 after Nu Skin reported disappointing second-quarter results. The stock closed at $48 on August 7.
Nu Skin, based in Provo, Utah, uses multilevel marketing to move its products. Like Herbalife (HLF), which uses a nearly identical business model, Nu Skin has suffered through and survived numerous investigations into its sales practices.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
The most recent inquiry was conducted by the government of China, where Nu Skin derived $1.4 billion in revenue (43% of total sales) last year. The investigation caused Nu Skin to halt sales and recruiting efforts in China for several months. However, analysts apparently underestimated the extent of the damage. When they saw the latest financial results, they started rapidly cutting their earnings estimates. But the share price has fallen far more precipitously than those estimates, and Nu Skin now sells for just 9 times projected year-ahead profits. Granted, estimates may come down more, but the stock still looks awfully cheap.
Sure, I wish I’d bought at $43.50. But I don’t mind buying into companies that have been severely punished for a temporary earnings shortfall. Would I buy it today at $48? Probably. So I’m going to sit still and hope that all of the bad news is out.
China, alas, is not the only issue weighing on Nu Skin’s stock. The shares are apparently feeling the fallout from the long-running battle between Herbalife and hedge fund manager Bill Ackman, who claims that the weight-loss and nutrition-supplement company is a Ponzi scheme. Ackman’s fund sold short $1 billion worth of Herbalife shares last year, betting that they would lose value. Regardless of whether Ackman is right or wrong, the sales practices he criticizes are common to most of the multilevel marketing industry.
Multilevel marketing companies can be dicey prospects because they usually involve selling products to salespeople, who use the products in demonstrations to sell more products to their friends. Salespeople also recruit other salespeople, who also buy the products. If a company’s products are stale, ineffective or simply unpopular, sales are limited to the company’s own salespeople. Without new customers, a multilevel marketer collapses.
Right focus. I don’t think either Nu Skin or Herbalife is on the verge of collapse. Before Nu Skin’s China-related stumble, both outfits had been enjoying strong revenue and earnings increases. It’s hard to pull off those kinds of numbers for long stretches (both companies are more than 30 years old) through a Ponzi scheme unless you’re completely cooking the books. That seems unlikely in these instances. And although I think Herbalife, at $50, is also a bargain, I prefer Nu Skin because of its focus on anti-aging products, which resonates with me and my baby boomer friends as we try to convince the world that we’re still in our thirties. Unfortunately, the stock itself is doing little for my youthful appearance; its recent drop has already given me a few new gray hairs.
Get Kiplinger Today newsletter — free
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.
-
Premium Tax Credit: Are You Eligible For This Health Insurance Tax Break?
Tax Credits The tax credit can help qualifying individuals pay for coverage from the Affordable Care Act’s health insurance marketplace.
By Gabriella Cruz-Martínez Published
-
Winners and Losers of Fed Rate Cuts
Navigating interest-rate changes can seem daunting, but these areas of the fixed-income market could perform better (or worse) than others.
By Jeffrey R. Kosnett Published
-
How to Beef Up Your Portfolio Against Inflation
investing These sectors are better positioned to benefit from rising prices.
By Karee Venema Published
-
Taxable or Tax-Deferred Account: How to Pick
Investing for Income Use our guide to decide which assets belong in a taxable account and which go into a tax-advantaged account.
By Nellie S. Huang Published
-
Smart Investing in a Bear Market
investing Here's how to make the most of today’s dicey market.
By Anne Kates Smith Published
-
How to Open a Stock Market Account
investing Investing can be fun, but you need a brokerage account to do it. Fortunately, it’s easy to get started.
By Rivan V. Stinson Published
-
The Right Dividend Stock Fund for You
Becoming an Investor Dividend stock strategies come in many different flavors. Here's what to look for.
By Adam Shell Published
-
Alternative Investments for the Rest of Us
Financial Planning These portfolio diversifiers aren't just for the wealthy.
By Adam Shell Published
-
When Actively Managed Funds Are Worth It
Becoming an Investor For some investment categories, choosing an actively managed fund makes sense.
By Adam Shell Published
-
Make Your Portfolio More Defensive
Becoming an Investor Risk is rising on Wall Street. Make sure you're prepared.
By Adam Shell Published